Sentiment Summary
Recent Events
Low importance estimated as no market reaction has occurred yet; Q2 2026 earnings report scheduled.
Ex-dividend date on June 16, 2026, for the final dividend of RMB 1.43 per 10 shares, scheduled to be paid on July 13, 2026. Low importance estimated as the dividend amount is within historical norms, scheduled.
Ex-dividend date (2026-06-12) for the proposed 2025 final dividend of HK$0.169 per share is scheduled.
Annual Meeting of Stockholders on 2026-06-10, with proposals including the election of directors and an expansion of the 2023 Equity Incentive Plan scheduled.
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
The 2026 Annual Meeting of Stockholders is scheduled for June 3, 2026, including a proposal to increase the number of shares reserved for the 2020 Equity Incentive Plan by 16,000,000. A low impact is estimated due to potential share dilution, scheduled.
Estimated low impact as such events typically provide incremental updates; Investor Day for analysts and institutional investors scheduled.
Adjustment to the conversion price of EUR 1.5 billion convertible bonds from HK$101.13 to HK$99.80 effective May 19, 2026; technical adjustment with minimal price impact expected, scheduled.
Ex-dividend date for the 2025 final dividend of HK$1.08 per share on May 15, 2026, with payment scheduled for June 1, 2026; expected to cause a 1-2% price adjustment, scheduled.
Announced a share repurchase plan for A-shares with a total amount of RMB 500 million to RMB 1 billion, at a price not exceeding RMB 60.00 per share, announced on May 13, 2026. The shares will be used for employee incentives or cancellation. This large-scale buyback is estimated to have a price impact of ≥5%.
Received clinical trial approval from China's NMPA for HS-10541 tablets on 2026-05-13; estimated 5% impact due to innovative drug pipeline expansion.
On May 13, 2026, the company repurchased 1.063 million shares on the Hong Kong Stock Exchange for approximately HKD 12.3 million as part of an ongoing buyback program.
Subsidiary Fosun Pharma Industrial to sign an exclusive option agreement with AriBio for global licensing rights to Alzheimer's candidate AR1001; the strategic expansion is estimated to have a 1-5% price impact, expected.
The company repurchased 10 million of its own shares for approximately HK$10.93 million on May 13, 2026, as part of its ongoing buyback program. Importance is Low as routine share repurchases typically have a minor impact on share price; expected.
Announced that the first subject has been dosed in the Phase 1 clinical trial of ICP-054 (ZB021), a novel oral IL-17AA/AF inhibitor for autoimmune diseases. Early-stage clinical progress is estimated to have a low market impact (>1%).
Global strategic collaboration and licensing agreement with Bristol-Myers Squibb (BMS) for 13 early-stage programs in oncology, hematology, and immunology, with a potential value of up to $15.2 billion and upfront/near-term payments of $950 million; the high deal value is estimated to result in a price impact exceeding 10%, scheduled
Controlling shareholders, Chairman Mr. Ye Xiaoping and Director Ms. Cao Xiaochun, received a case filing notice from the China Securities Regulatory Commission (CSRC) on May 12, 2026, for an investigation into suspected violations regarding information disclosure of historical shareholding changes. This regulatory action against top management is estimated to have a price impact of ≥10%.
Announced that its associate, Legend Biotech (LEGN), reported strong Q1 2026 results on May 12, 2026, with CARVYKTI net sales increasing 62% year-over-year to approximately $597 million and a narrowed net loss.
JD Health reported Q1 2026 revenue of RMB 19.47 billion (+17% YoY) and non-IFRS net profit of RMB 1.87 billion (+6.0% YoY); stock price surged over 6%.
The Board authorized a US$1.0 billion share repurchase program on May 12, 2026, for a 48-month period.
Launched the TurboCHO™ Protein Expression Kit, a new reagent for antibody expression, at the PEGS Summit in Boston on May 12, 2026, aimed at accelerating drug discovery.
Completion of the public tender offer for Vietnam's Imexpharm Corporation (IMP) on May 11, 2026, securing a controlling stake of approximately 67.88% of voting shares. Low importance estimated as the market impact is expected to be limited, scheduled.
Major institutional investor Baillie Gifford & Co. reduced its stake in the company's H-shares from 6.12% to 5.61% on 2026-05-11; this minor reduction is estimated to have a >1% price impact.
IBI363 is expected to receive its third Breakthrough Therapy Designation from the NMPA on May 10, 2026; this clinical milestone's low market impact is expected
HS-20093 granted Breakthrough Therapy Designation by China's NMPA for esophageal squamous cell carcinoma on 2026-05-09; estimated 5% impact from accelerated approval path.
The NMPA is expected to approve the Mazdutide pen for type 2 diabetes on May 8, 2026; this core product approval's medium market impact is expected
The Board of Directors proposed the adoption of a 2026 Equity Incentive Plan on May 8, 2026. Importance is Low as administrative corporate actions generally have limited immediate market impact; expected.
Submitted an application to the New York State Department of Health (NYSDOH) seeking authorization for its blood-based molecular profiling test, Caris Assure, to be performed on specimens from New York.
Reported Q1 2026 financial results, with revenue surging 79% year-over-year to $216.2 million and net loss narrowing to $0.5 million from a $103 million loss in Q1 2025. The company also reported its fourth consecutive quarter of positive adjusted EBITDA.
Reported Q1 2026 revenue of $301.7 million, a 48% increase year-over-year, beating analyst expectations. The company raised its full-year 2026 revenue guidance to $1.30-$1.32 billion. High importance estimated due to significant revenue beat and guidance raise; expected.
On May 7, 2026, the company reported Q1 2026 financial results, with revenue of $37.2 million missing analyst expectations, while the non-GAAP loss per share of $0.12 was better than forecast. Following the release, the stock price declined by approximately 15%. The company also narrowed its full-year 2026 revenue guidance to a range of $165 million to $175 million.
Reported Q1 2026 financial results on May 7, 2026. Revenue was $150.8 million, a 3% decrease YoY, but a 9% increase when excluding a one-time license revenue item from Q1 2025. EPS of -$0.10 beat estimates, but the stock price dropped nearly 10% following the release.
Natera reported Q1 2026 financial results. Revenue of $696.6 million beat analyst expectations, but EPS of -$0.60 missed forecasts. The company raised its full-year 2026 revenue guidance. The stock fell 9.69% in after-hours trading following the announcement.